Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA
Want to see KZIA full AI Analyst Report?
Total Valuation
Kazia Therapeutics has a market cap or net worth of $157.80M. The enterprise value is -$36.43M.
Market Cap$157.80M
Enterprise Value-$36.43M
Share Statistics
Kazia Therapeutics has 11,335,992 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,335,992
Owned by Insiders―
Owned by Institutions9.82%
Financial Efficiency
Kazia Therapeutics’s return on equity (ROE) is 2.49 and return on invested capital (ROIC) is 172.61%.
Return on Equity (ROE)2.49
Return on Assets (ROA)-3.42
Return on Invested Capital (ROIC)172.61%
Return on Capital Employed (ROCE)1.78
Revenue Per Employee7.00K
Profits Per Employee-3.45M
Employee Count6
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kazia Therapeutics is ―. Kazia Therapeutics’s PEG ratio is 0.00768.
PE Ratio―
PS Ratio248.45
PB Ratio-1.26
Price to Fair Value-1.26
Price to FCF-0.79
Price to Operating Cash Flow-4.76
PEG Ratio0.00768
Income Statement
In the last 12 months, Kazia Therapeutics had revenue of 42.00K and earned -20.70M in profits. Earnings per share was -18.90.
Revenue42.00K
Gross Profit42.00K
Operating Income-14.22M
Pretax Income-22.45M
Net Income-20.70M
EBITDA-13.28M
Earnings Per Share (EPS)-18.90
Cash Flow
In the last 12 months, operating cash flow was -13.22M and capital expenditures 4.14M, giving a free cash flow of -9.07M billion.
Operating Cash Flow-13.22M
Free Cash Flow-9.07M
Free Cash Flow per Share-0.80
Dividends & Yields
Kazia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.21
52-Week Price Change113.17%
50-Day Moving Average12.71
200-Day Moving Average9.03
Relative Strength Index (RSI)56.60
Average Volume (3m)209.48K
Important Dates
Kazia Therapeutics upcoming earnings date is Aug 28, 2025, TBA (Confirmed).
Last Earnings DateFeb 19, 2025
Next Earnings DateAug 28, 2025
Ex-Dividend Date―
Financial Position
Kazia Therapeutics as a current ratio of 0.35, with Debt / Equity ratio of 0.21%
Current Ratio0.35
Quick Ratio0.35
Debt to Market Cap0.04
Net Debt to EBITDA0.30
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Kazia Therapeutics has paid -1.75M in taxes.
Income Tax-1.75M
Effective Tax Rate0.08
Enterprise Valuation
Kazia Therapeutics EV to EBITDA ratio is -0.49, with an EV/FCF ratio of -0.49.
EV to Sales154.43
EV to EBITDA-0.49
EV to Free Cash Flow-0.49
EV to Operating Cash Flow-0.49
Balance Sheet
Kazia Therapeutics has $69.39M in cash and marketable securities with $98.71K in debt, giving a net cash position of $69.29M billion.
Cash & Marketable Securities$69.39M
Total Debt$98.71K
Net Cash$69.29M
Net Cash Per Share$6.11
Tangible Book Value Per Share-$8.57
Margins
Gross margin is 100.00%, with operating margin of -33850.00%, and net profit margin of -49290.48%.
Gross Margin100.00%
Operating Margin-33850.00%
Pretax Margin-53447.62%
Net Profit Margin-49290.48%
EBITDA Margin-31626.19%
EBIT Margin-33850.00%
Analyst Forecast
The average price target for Kazia Therapeutics is $26.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$26.25
Price Target Upside307.61% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-98.25%
EPS Growth Forecast76.83%